SCHEMBL12801643

SCHEMBL12801643

COc1cc(Nc2nccc(-c3cccc(N)c3)n2)cc(OC)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.82
MEN1 O00255 1/20 0.82
NPC1 O15118 1/20 0.82
RAB9A P51151 1/20 0.82
KMT2A Q03164 1/20 0.82
CDK5R1 Q15078 1/20 0.82
PLK1 P53350 1/20 0.65
CAMK2D Q13557 1/20 0.63
PIK3CG P48736 5/20 0.61
PIK3CA P42336 4/20 0.61
PIK3CB P42338 4/20 0.61
SRC P12931 3/20 0.58
ABL1 P00519 2/20 0.58
BCR P11274 2/20 0.58
EGFR P00533 2/20 0.58
PRKACA P17612 1/20 0.58
PRKACG P22612 1/20 0.58
PRKACB P22694 1/20 0.58
ZAP70 P43403 2/20 0.57
SYK P43405 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939794 0.92 CDK5 (0.80) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL6976454 0.86 ZAP70 (0.71) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL4732715 0.85 PIK3CG (0.61) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL823915 0.83 CAMK2D (0.82) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL12275201 0.82 MEN1 (0.61) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL27116598 0.82 PIK3CG (0.83) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL12801671 0.82 CDK5 (0.66) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL19427477 0.82 PIK3CG (0.67) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL27444270 0.82 PLK1 (0.78) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL12801287 0.82 PLK1 (0.82) CDK5MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011046970-A1 AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON MYREXIS, INC. (US) 2011-04-21 WO disclosed